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Abstract
The recent emergence and widespread abuse of new classes of compounds on the
designer drug market as “legal” alternatives to scheduled drugs such as Ecstasy has prompted
interest in the development of analytical methods for their detection and characterization.
Synthetic cathinones, which are structurally similar to amphetamines, are commonly advertised
as a “legal highs” or “herbal highs,” and are marketed under names such as “bath salts” and
“plant food.” To avoid drug abuse legislation, a “not for human consumption” warning is
typically printed on the label. Their ready availability on the Internet and in “head” shops,
convenience stores, and even gas stations has spurred the popularity and abuse of these drugs for
their euphoric/stimulant effects. The dramatic increase since 2009 in U.S. drug seizures
involving cathinones, coupled with a significant rise in calls to poison control centers,
emergency room visits, and even deaths due to synthetic cathinone intoxication, have prompted
37 states to ban these substances. In October 2011 the U.S. Drug Enforcement Agency exercised
its emergency scheduling authority to temporarily designate three synthetic cathinones as
Schedule I substances under the Controlled Substances Act.
The current study explores the development of an analytical method based on headspace
and direct immersion solid-phase microextraction (HS-SPME and DI-SPME, respectively)
coupled with gas chromatography-mass spectrometry (GC-MS) for the rapid laboratory
confirmation of synthetic cathinones in oral fluid. Target analytes included butylone,
diethylpropion, flephedrone, mephedrone, methedrone, MDPV, methylone, and naphyrone.
Results of method optimization experiments designed to maximize SPME recoveries of
cathinones from oral fluid are presented. Parameters investigated include incubation/extraction
temperature, sample pH and salting out effects. In-matrix derivatization with ethylchloroformate
and 2,2,2-trichloroethylchloroformate was explored. The mass spectrometric fragmentation of
the alkylchloroformate derivatives was characterized and selectivity advantages were
summarized. An internal standard calibration method was developed using matrix-matched
calibrators and deuterated analogs of the target drugs as internal standards. Validation data
including limit of detection, limit of quantification, and accuracy of quantification in oral fluid
are presented.
Keywords: cathinone, bath salts, solid-phase microextraction, derivatization,
ethylchloroformate, 2,2,2-trichloroethylchloroformate, oral fluid, drug detection
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Chapter 1:
Introduction
1.1: Background
In recent years synthetic cathinones have become an increasingly popular and dangerous
class of designer drug, abused by many individuals worldwide due to their ease of acquisition,
variable legal status and hallucinogenic/euphoric effects. This most recent designer drug craze,
which began in Western Europe in 2007, spread to the United States in 2010 [1]. These synthetic
legal intoxicating drugs (SLIDs) are widely available over-the-counter in gas stations,
convenience stores, and “head” shops, as well as on the Internet [2]. Synthetic cathinones are
derivatives of cathinone ((S)-2-amino-1-phenyl-1propanone), a naturally occurring compound found in the
leaves of the Cathu edulis (khat) plant [3]. As of 1993
cathinone was a scheduled drug in the United States
Figure 1: Commercial “bath
salts” advertised as plant food.
http://www.emcdda.europa.eu/pu
blications/drug-profiles/syntheticcathinones

under the Controlled Substance Act. The first appearance
of synthetic cathinones dates back to the late 1930’s. The
former Soviet Union used methcathinone as an

antidepressant in the 1930’s and an appetite suppressant in the 1950’s [4, 5]. Synthetic analogs of
cathinone are commonly advertised as “legal highs” and are typically marketed as “bath salts” or
“plant food (Figure 1).” In order to avoid regulation as a drug of abuse, a “not for human
consumption” warning is typically printed on the label [3]. Popular brand names of these
synthetic drugs range from “Ivory Wave,” “White Lighting,” “Meow-meow,” “Blow,” and
“Cloud 9” to “Bohemian Bath Salts,” “Columbian Odorizer” and “Serenity” [4]. The major
structural difference between synthetic cathinones and amphetamine type drugs is the presence
of the beta-keto (bk) moiety on the benzyl side chain (Figure 2).
9

The most prevalent synthetic cathinones that are being marketed as “legal highs” include
3,4-methylenedioxypyrovalerone (MDPV), 3,4-methylenedioxy-N-methylcathinone (bkMDMA, or methylone) and 4-methylmethcathinone (4-MMC, or mephedrone). These three
drugs represent 98% of all synthetic cathinones currently on the market [6]. Other synthetic
cathinones of interest are bk-N-methylbenzodioxolylpropylamine (bk-MBDB, or butylone), 4-

Figure 2: Molecular structures of 8 synthetic cathinones of interest in this study

methoxymethcathinone (bk-PMMA, PMMC, or methedrone), napthylpyrovalerone (NRG-1, or
naphyrone), 4-fluoromethcathinone (4-FMC, or flephedrone), and 2-(diethylamino)-1-phenyl1-propanone (DI, amfepramone, or diethylpropion) [2]. Chemical and structural data for these
drugs is provided in Figure 2. These eight compounds are the target analytes explored in this
study.
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1.2: Pharmacology of Synthetic Cathinones
Synthetic cathinones possess similar stimulatory and hallucinogenic properties to those of
Schedule I and II stimulants [6]. The extracellular increase of monoamines caused by synthetic
cathinones is believed to produce the stimulatory and hallucinogenic effects of these drugs [7].
The common structural feature of both synthetic cathinones and other amphetamine-type
stimulants is a phenyl group connected via a two-carbon chain to an amino group, similar to that
of dopamine (Figure 3) [8]. While the desired effect of synthetic cathinones is a euphoria similar
to that of amphetamine or methamphetamine, adverse effects are being increasingly reported by

Figure 3: Structural similarities between dopamine, amphetamine, MDMA and cathinone.

hospitals and poison control centers [1, 9-10]. Routes of administration include sublingual,
intranasal, intravenous, rectal and inhalation [11]. On October 21, 2011, the United States
Department of Justice (USDoJ) and the Drug Enforcement Administration (DEA) designated
three synthetic cathinones – MDPV, mephedrone and methylone – as temporary Schedule 1
substances under the Federal Analog Act, which controls these substance for up to eighteen
months while the DEA and Department of Health and Human Services assess whether these
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substances should be permanently controlled [12-13]. Various states have also enacted their own
legislation for the scheduling of other synthetic cathinones.
MDPV, an analogue of pyrovalerone, a stimulant used to treat chronic fatigue, is known
to be a dopamine (DA) and norepinephrine (NE) reuptake inhibitor [14, 15]. Like MDMA and
methamphetamine, MDPV has been experimentally shown to increase extracellular levels of
dopamine in mice brains, although with less potency [16]. It has no documented medical uses
and produces stimulatory effects similar to those of MDMA [12,14].
Mephedrone also possesses stimulatory properties similar to those of MDMA [17]. While
the mechanism of action has not been extensively studied, it is believed that mephedrone acts as
a monoamine reuptake inhibitor in addition to stimulating the presynaptic release of monoamines
[17]. Mephedrone has been shown experimentally to increase the extracellular concentration of
both serotonin and dopamine in rat brains [18,19]. First synthesized in 1929, it was the sixth
most popular drug of abuse in Europe only two years after it was classified as a drug of abuse
(DOA) in 2007 [17,20].
Methylone has no legitimate medical uses, although it was developed during research
into anti-depressant and anti-Parkinsonian agents [21]. Methylone initiates an increase in
dopamine, norepinephrine and serotonin from cells that express these specific monoamine
transporter proteins [22].
Despite their recent emergence, a variety of methods have already been reported for the
detection, quantification and characterization of synthetic cathinones using GC-MS [4, 23-34],
liquid chromatography-mass spectrometry (LC-MS) [23, 25, 31, 33, 35, 36], high performance
liquid chromatography (HPLC) [37], Fourier transform infrared spectroscopy (FTIR) [27, 38],
Fourier transform Raman spectroscopy (FT-Raman) [27], nuclear magnetic resonance (NMR)
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[24, 26-27, 38-39] and immunoassay (IA) [36, 40]. MDPV and butylone have been known to
cause false positive results in amphetamine/Ecstasy [36] and phencyclidine (PCP) [40] IA drug
screens, respectively.
1.3: Solid-Phase Microextraction (SPME)
Solid-phase microextraction (SPME) is a fast, efficient, affordable, sensitive and solventfree extraction technique that allows for high-throughput and online coupling of sample
preparation and separation [41-46]. It also avoids the typical problems (i.e., sample loss, dilution

Figure 4: Schematic of HS-SPME in combination with GC-MS

and/or contamination) associated with other extraction techniques such as liquid-liquid
extraction, solid-phase extraction, and purge-and-trap [47]. Most extraction methods require a
large amount of technical expertise to obtain accurate and reproducible results and often involve
multiple steps, increasing the chance of sample loss [48]. In contrast, SPME is simple to
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implement, readily automated and easy to couple with GC or LC. SPME was invented in 1989
by Pawliszyn and colleagues for analysis of water pollutants [49]. Two commonly used modes of
SPME are headspace (HS-SPME) and direct immersion (DI-SPME). HS-SPME is well suited
for analysis of volatile compounds while DI-SPME is well suited for polar and non-volatile
compounds [44]. Both use a fused silica fiber coated with a polymeric organic liquid which acts
as the extraction medium. The fiber is encased in a stainless steel sheath to prevent mechanical
damage during septum piercing. In HS-SPME (see Figure 4) the liquid or solid sample is
capped and incubated, driving the analytes of interest into the headspace above the sample. Once
a dynamic equilibrium is reached the SPME needle pierces the septum of the cap and the SPME
fiber is exposed to the headspace, allowing the gaseous analytes to adsorb onto the fiber phase.
After the desired extraction time, the fiber (with adsorbed analytes) is retracted back into its

Figure 5: Schematic of DI-SPME in combination with GC-MS
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protective sheath and the needle is removed from the sample vial. If GC-MS is being utilized for
extract analysis, the SPME needle subsequently enters the GC injection port and the SPME fiber
is exposed. The analytes are then thermally desorbed off the fiber and concentrated at the head of
the GC column. Direct immersion (DI) SPME is identical to HS-SPME except the SPME fiber is
exposed directly to the liquid sample matrix (Figure 5), removing volatility issues that can
render HS-SPME ineffective. When employing HS-SPME, sample pretreatment and preheating
can increase the volatility of some substances. Pretreatment for amphetamine type drugs often
involves adjusting the sample to an alkaline pH (to maintain the free base form of the drug) and
addition of salt. Agitation of the sample in both DI and HS-SPME allows for decreased sampling
time by decreasing the time for dynamic equilibrium to be achieved. SPME is extremely well
suited for the extraction of volatile and semi-volatile compounds from a variety of matrices,
making it ideal for biological sample analysis [50]. On-fiber as well as in-matrix analyte
derivatization is also compatible with SPME [51].
1.4: SPME: Methodology and Theory
SPME is a multiphase complex equilibration process, which is completed once a
dynamic equilibrium is achieved between the sample matrix and the headspace and the
headspace and the fiber coating [52]. The equilibrium conditions are best described by Equation
1, where n is the mass of the analyte extracted by the coating, Kfs is a fiber coating–sample
matrix distribution constant, Khs is the headspace–solution equilibrium constant, Vf is the fiber
coating volume, Vs is the sample volume, Vh is the headspace volume, and c0 is the initial
concentration of a given analyte in the sample [52].

Equation 1:

𝑛=𝐾

𝐾𝑓ℎ 𝐾ℎ𝑠 𝑉𝑓 𝑉𝑠

𝑓ℎ 𝐾ℎ𝑠 𝑉𝑠 +𝐾ℎ𝑠 𝑉ℎ +𝑉𝑠

𝑐𝑜
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Various factors can affect the efficiency and sensitivity of SPME. In order to maximize
SPME recoveries, a variety of operational parameters need to be optimized. These parameters
include fiber size and nature and thickness of coating; agitation of the sample; sample pH; salting
out effects; incubation, extraction and desorption temperatures; and incubation, extraction, and
desorption times. Optimization of these parameters is necessary to achieve desirable detection
limits and to reduce sampling time. Sample pretreatment is simple and dependent upon the
chemical nature of the desired analytes.
1.5: Review of SPME in Analytical Toxicology
The use of SPME in analytical toxicology, reviewed by Pragst [52] and Kataoka [41], has
increased dramatically over the past decade. SPME-GC/MS is an ideal method for coupling the
extraction, detection and quantification of drugs of abuse in many different biological samples.
Merola and colleagues [53] developed a HS-SPME/GC-MS method for the determination and
quantification of amphetamines, ketamine, methadone, cocaine, cocaethylene, and THC in hair.
Miekisch and colleagues [34] used HS-SPME/GC-MS for the assessment of propofol
concentrations in human breath and blood. Hara and colleagues [54] used HS-SPME/GC-MS to
determine amphetamine and methamphetamine concentrations in human tissue. Recently, a
SPME/GC-MS method for the simultaneous detection of seventeen drugs of abuse and
metabolites in hair was developed by Aleksa and colleagues [32].
More relevantly, SPME has been used in combination with GC/MS for the detection of
many different types of drugs in oral fluid (OF). OF offers enormous advantages over other
biological matrices when attempting to determine if a subject is under the influence of a DOA at
the time of testing. While the levels of drugs in OF are often similar to that of plasma, OF can be
obtained under direct observation by non-medical personnel, making sample collection easier,
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faster and less subject to adulteration [55-56]. Although urine sample collection should be done
under direct supervision, subjects are often granted privacy to produce the specimen, allowing
for a higher chance of sample adulteration. Furthermore, urinalysis is only useful for establishing
recent use, rather than “under the influence” determinations, making it ineffective for roadside
testing [55]. A more comprehensive list of the advantages and disadvantages of OF drug
monitoring are outlined in Table 2.

Table 2: Advantages and Disadvantages of Oral Fluid Testing*
Advantages
Disadvantages
•
•
•
•
•
•
•
•
•

•

Observed collection
Noninvasive collection
Less stressful collection for cortisol levels
Decreased opportunity for adulteration when
compared to urine
Generally represents free plasma levels
Easier to obtain multiple samples than with urine or
plasma
Commercial screening assays are available
Oral fluid assays are technically easier than plasma
due to the lower content of proteins and lipids
Collection and screening may be done in the home
Risk of infection is lower with oral fluid than
plasma

•
•
•
•
•
•

•

Limited specimen volume
Low analyte concentrations
Interferences from food and/or
beverages
Contamination with oral, smoked,
inhaled or insufflation
Lack of standardized testing
procedures
If collection devices are used,
unknown concentration of analyte
Stimulation of oral fluid changes
the pH and drug concentration

*Reproduced from [56]

1.6: Oral Fluid and Drug Analysis
OF consists of saliva, gingival cervicular fluid, buccal and mucosal transudates, cellular
debris, bacteria, and residues of ingested products [55]. The salivary glands, which are highly
perfusable, allow for the rapid diffusion of DOA in blood to OF, with positive detection of drugs
occurring within minutes of use [57].
The most common route in which ionized DOA and their ionized metabolites appear in
oral fluid is through passive diffusion from blood [55]. Intranasal administration and inhalation
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can also deposit DOA in oral fluid [55]. Passive diffusion is affected by salivary pH, chemical
properties of the DOA, concentration of nonionized DOA/metabolites, drug-protein binding, and
membrane characteristics [57]. Basic drugs are often found in higher concentrations in plasma
compared with OF due to the relative acidity of saliva [57].

1.7: Oral Fluid and SPME for Drug Analysis
Fucci and colleagues [58] developed a SPME (HS and DI) method for the detection of
methadone, cocaine, cocaethylene, amphetamine, methamphetamine, MDMA, 3,4methylenedioxyethylamphetamine (MDEA), N-methyl-1-(3,4-methylenedioxyphenyl)-2butanamine (MBDB), cannabidiol, THC and cannabinol in OF. Limits of detection (LOD) and
limits of quantification (LOQ) for these analytes ranged from 1-50 ng/mL for DI-SPME and 1250 ng/mL for HS-SPME [58]. Souza and colleagues [59] developed a DI-SPME method to
detect amphetamine, methamphetamine, fenprorex and diethylpropion in OF after in-matrix
derivatization with propylchloroformate, which produced detection limits of 0.5-2 ng/mL [58].

1.7: Project Goals
Much of the published literature on the detection, quantification and characterization of
synthetic cathinones explores only one or two cathinone analogs at a time. The few studies that
have been developed for screening multiple synthetic cathinones have focused on LC-MS
separation and detection. At this time no study has used SPME to isolate synthetic cathinones
from oral fluid. The goal of the present study was to develop a rapid and reliable method based
on SPME/GC-MS for the detection and quantification of eight unique and commonly abused
synthetic cathinones (see Figure 2) in OF. Because MDMA tablets often contain synthetic
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cathinone impurities or are comprised completely of synthetic cathinones [60], MDMA was also
included as a target analyte in this study.
Various derivatization schemes with alkylchloroformate reagents were investigated to
increase the volatility and improve the chromatographic characteristics of target analytes
possessing a secondary amine group. Each analyte and its alkylchloroformate derivative was
characterized by electron impact mass spectrometry. HS and DI-SPME were compared for
relative efficiency and reproducibility of extraction of the target analytes from OF.
SPME parameters including incubation and extraction temperature and sample
pretreatment were optimized. Calibration curves using deuterated internal standards (I.S.) were
produced. Analytical figures of merit including limits of detection and quantification (LOD,
LOQ) and accuracy were determined. Finally, the optimized method was applied to a
commercially available saliva drug test collection device to demonstrate proof of concept.
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Chapter 2:
Experimental Methods
2.1: Chemicals and Reagents
Certified analytical reference standards for MDPV, methylone, mephedrone,
mephedrone-d3 diethylpropion, butylone, butylone-d3, methedrone, naphyrone, flephedrone,
amphetamine, methamphetamine, MDMA, MDMA-d5, MBDB, MDA, MDEA, PMA and
PMMA were purchased from Cerilliant Corporation (Round Rock, TX). All certified standards
and working standard solutions were stored at 4oC in clear plastic storage containers.
Ethylchloroformate (ECF) and 2,2,2-trichloroethylchloroformate (TCECF) were obtained from
Sigma Aldrich (Bellefonte, PA) and stored at 4oC.

2.2: Individual Working Standard and Mixed Calibration Standard Preparation
Stock aqueous solutions (~40 μg/mL) of each analyte were prepared by appropriate
dilution of certified reference standards (1.0 mg/mL in methanol) obtained from Cerilliant using
an absolute mass method. Mixed aqueous calibration standards with concentrations of 5, 10, 20,
50, 100, 200, 400, 800, 1600, 4800, and 8000 ng/mL were prepared from these stock solutions
using a serial dilution method.
2.3: SPME/GC-MS Analysis
Samples were analyzed using a Thermo-Fisher Trace Ultra DSQ II with a TriPlus
autosampler equipped with an aluminum heating block which allowed for stable, programmable
sample incubation and extraction. SPME vials (10 mL) and septum caps were purchased from
Thermo Fisher (Kalamazoo, MI). The SPME fiber was a 24-gauge autosampler-compatible 100
μm polydimethylsiloxane (PDMS) fiber (Supelco Corp, Bellefonte, PA) which was conditioned
for 30 minutes at 250oC before use. The GC column was a Restek Rxi-5ms (15 m x 0.25 mm x
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0.25 μm) 5% diphenyl/ 95% dimethylpolysiloxane (Restek Corp., Bellefonte, PA). Optimal
analyte separation was obtained using the following GC oven temperature program: initial
temperature 80oC (3 min hold); ramp 1 at 40oC/min to 140oC; ramp 2 at 8oC/min to 210 oC; ramp
3 at 40oC/min to 280oC (3 minute hold). Helium was used as a carrier gas at a flow rate of 1
mL/min. Splitless injection at 250 oC was employed with a splitless time of 2.0 minutes. The MS
transfer line was maintained at 250oC. The MS was operated in the electron impact ionization
mode (70 eV). The ion source was maintained at 200oC. MS data acquisition was initiated at 6
min and was performed in full scan (40-400 m/z) mode for SPME optimization experiments.
2.3.1: Headspace solid-phase microextraction (HS-SPME). Aqueous samples were incubated for
10 minutes at the optimized temperature (see below) in the aluminum block of the autosampler.
The PDMS fiber was then introduced to the headspace of the sample and extraction took place
for 10 minutes at the optimized temperature. The extracted analytes were then thermally
desorbed at 250oC for 6 minutes (optimized in earlier work for MDMA) in the splitless injection
mode.
2.3.2: Direct-immersion solid-phase microextraction (DI-SPME). The sample was introduced to
the aluminum heating block at 70oC. The 100 μm SPME fiber was then directly immersed into
the sample for 10 minutes. In order to insure direct fiber exposure the fiber sampling depth was
set to its maximum depth (35 mm) and the samples were diluted with 8.0 mL of water to raise
the volume of the sample to an adequate sampling height.
2.4: Sample Pretreatment
HS-SPME samples were pretreated with KOH (1.4 M) to a final sample pH of 10 and
saturated with NaCl. DI-SPME samples were pretreated with KOH and diluted with deionized
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water to bring the aqueous sample to an appropriate depth for automated sampling. Vials were
hermetically sealed with crimp tops.
2.5: HS-SPME Parameter Optimization
Incubation/extraction parameters were optimized by running triplicate analyses of ~320
ng/mL mixed standards at 50, 60, 70, 80, 90 and 100oC and plotting the absolute area of the base
peaks of each analyte after derivatization with ECF. A subsequent temperature optimization was
run at 80, 90, 100, 110, 120 and 130oC. The optimal temperature for analysis of all samples was
determined by averaging the optimal incubation/extraction temperatures determined for each
individual analyte.
2.6: Oral Fluid Collection and Drug Fortification
Drug free oral fluid for spike recovery studies and for use as a negative control was
collected daily by expectoration from a drug negative user prior to sample preparation.
2.7: SPME with In-Matrix Derivatization
For derivatization studies, 50 μL of derivatizing reagent were added directly to a SPME
vial containing 400 μL of the aqueous or oral fluid sample, 400 μL of 1.4 M KOH (pH=10) and
saturated with salt (HS-SPME only).
2.8: Preparation and GC-MS Analysis of Derivatized Standards
For retention time determination and mass spectral characterization of derivatized
analytes, derivatized standards for liquid injection were prepared in the following manner: 500
uL of an individual stock aqueous standard was spiked into a glass screw top conical test tube, 50
uL of derivatizing reagent (ECF) was added and the tube was vortexed for 1 min. The tube was
capped and incubated at 80oC for 15 minutes. Derivatized analytes were then back extracted into
1 mL of ethyl acetate. The ethyl acetate layer was transferred to a GC autosampler vial for
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subsequent GC-MS analysis. Prior to injection the GC syringe was prewashed twice in hexane
(2 x 5.0 uL), twice in ethyl acetate (2 x 5.0 uL) and twice with the sample (2 x 2.0 uL). The
sample (1.0 uL) was injected at 280oC and GC-MS was performed under the operating
conditions described above.
2.9: Calibration Curves
HS-SPME calibration standards were prepared by fortifying 400 μL of oral fluid with
aqueous mixed analyte solutions to achieve final concentrations of 1, 2, 4, 10, 20, 40, 80, 160
and 320 ng/mL. DI-SPME calibration standards were prepared in the same manner with final
concentrations of 20, 40, 80, 160 and 320 ng/mL; these calibrators were subsequently diluted
with 8 mL deionized water to bring the volume to an appropriate sampling depth for DI as
discussed above. MDMA-d5 (30 ng/mL) was used as an I.S. for DI-SPME while mephedrone-d3
and butylone-d3 (96 ng/mL) were used as I.S. for HS-SPME. Each calibration standard was run
under the optimized SPME parameters.
2.10: Accuracy
Accuracy was assessed by analysis of blind high (240 ng/mL) and low (60 ng/mL)
fortified samples which were quantified off the calibration curve run that day. Each calibrator
and blind sample was fortified with MDMA-d5 internal standard at a concentration of 30 ng/mL.
2.11: Demonstration of Method Applicability to Commercial Saliva Collection Kit
For demonstration of proof-of-concept for the DI-SPME method, analysis was performed
using an Intercept oral fluid collection device (Bethlehem, PA). To simulate the saliva collection
process, the cotton swab was immersed for 5 minutes in 2 mL of negative control saliva in a
conicle test tube which had been pre-fortified with the target analytes (16 ng/mL). To
accommodate the saliva swab 4 mL of deionized water was added to conical tube. The swab was
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then stored in preservative buffer supplied with the commercial kit. The swab and buffer were
subsequently transferred to a 10 mL SPME vial and analyzed in the DI-SPME manner described
above.
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Chapter 3:
Results and Discussion
3.1: Cathinone Recovery using HS-SPME
Initial HS-SPME experiments demonstrated that while HS-SPME was a suitable method
for the isolation of 3o cathinones from aqueous solution, underivatized 2o cathinones were not
recovered (Figure 6).

Figure 6: Resulting chromatogram following HS-SPME of an underivatized aqueous standard of
mixed cathinones (320 ng/mL), demonstrating the recovery of 3o cathinones and MDMA, while
2o cathinones are absent. SPME conditions: 100 μm PDMS fiber, 70oC extraction/incubation
temp, 10 min extraction time, 6 min desorption time at 250 ˚C. GC-MS parameters as described
in the experimental section.
It is hypothesized that intermolecular hydrogen bonding between neighboring 2o cathinones in
solution (Figure 7) is sufficiently strong so as to preclude their partitioning into the headspace.
In contrast, the 3o cathinones and MDMA (which lacks a β-keto moiety and does not hydrogen
bond in a similar manner to 2o cathinones) are sufficiently volatile and efficiently recovered
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Figure 7: Hypothesized intermolecular bonding schematic which prevented underivatized 2o
cathinones from entering the gaseuous, making them incompatible with HS-SPME.
using HS-SPME. To overcome this volatility limitation for 2o cathinones, both direct immersion
(DI)-SPME and in-matrix derivatization of the 2o amine functional group with
alkylchloroformate derivatizing reagents was investigated as a means to eliminate the
intermolecular hydrogen bonding and allow the cathinones to enter the HS for SPME extraction.

3.2: Effect of ECF Derivatization on Cathinone Recovery Using HS-SPME
The advantages of ECF derivatization on the recovery of cathinones became immediately
apparent, as shown in Figure 8. 20 cathinones were easily derivatized within the aqueous matrix
(referred to as “in-matrix” derivatization) to their ethylcarbamate analogs using ECF, and were
readily extracted from the headspace above incubated oral fluid samples (Figure 8a).
Unfortunately, in the presence of the ECF derivatizing reagent the 3o cathinones were either
inefficiently extracted (Figure 8b) or not extracted at all (Figure 8c). While it was initially
expected that the 3o cathinones would be unaffected by the ECF reagent, it is now hypothesized
that the reagent may in fact react with the tertiary amines at the amine or carbonyl functional

26

groups to form an unanticipated derivative that is either non-volatile or does not partition into the
PDMS fiber film. This hypothesis is discussed in further detail in section 3.7.

Figure 8: Resulting chromatogram following HS-SPME of ECF-derivatized mixed cathinone
standard in oral fluid. Figure 3a shows that 2o cathinones (320 ng/mL) were successfully
extracted from the HS as their ECF derivatives following addition of 50 μL of the ECF reagent
directly to the oral fluid matrix. Figures 3b and 3c show that 3o cathinones (320 ng/mL and 80
ng/mL, respectively) were inefficiently recovered (3b) or not recovered at all (3c) in the presence
of ECF derivatizating reagent. SPME conditions as in Figure 6.
3.3: Effect of ECF Derivatization on GC Peak Shape of Cathinone Analogs
The conversion of the secondary amine functional group to a carbamate by derivatization
with ECF allowed for improved GC peak shapes of secondary cathinones (Figure 9). While the
GC peaks for the underivatized cathinones showed significant tailing (Figure 9a), those for
ECF-derivatized cathinones exhibit no tailing and are more Gaussian-shaped (Figure 9b).
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Figure 9: Resulting chromatogram following DI-SPME of underivatized (a) and ECFderivatized (b) mephedrone and flephedrone from oral fluid, showing the advantages of ECFderivatization on GC peak shape. SPME conditions as in Figure 7.

3.4: Effect of ECF- and TCECF- Derivatization on MS Selectivity of Cathinone Analogs
The 70 eV EI-mass spectra obtained for underivatized 2o cathinone analogs, shown in
Figure 10, illustrate that structurally similar cathinone compounds produce relatively nonselective fragmentation patterns which lack molecular ions and consist mainly of immonium ions
at m/z 58 or 72 depending on the particular compound [31, 61]. The lack of selectivity in the
mass spectra makes identification of structurally similar analogs extremely challenging in the
absence of authentic standards. To address these limitations, derivatization with
alkylchloroformates was investigated with the goal of producing analyte derivatives which
exhibit more unique fragmentation patterns and consequently provide for more adequate mass
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Figure 10: 70 eV MS of underivatized 2o cathinones

spectral discrimination of structurally similar cathinone analogs. Specifically, derivatization with
2,2,2-trichloroethylchloroformate (TCECF) and ethylchloroformate (ECF) was explored. These
reactants acylate 1o and 2o amines to produce carbamate derivatives (Figure 11). The
advantages of ECF derivatization for extraction of 2o cathinones and improved chromatographic
performance were described above. Here, the advantages of both ECF- and TCECFderivatization on MS selectivity are discussed.
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Figure 11: Derivatization reaction of 2o cathinone with ECF (11a) and TCECF (11b).

Figures 12 and 13 illustrate the improved MS selectivity that derivatization with ECF
and TCECF, respectively, provide. Derivatives were prepared by adding 50 uL of derivatizing
reagent to oral fluid fortified with an aqueous cathinone mixed standard (320 ng/mL) and
pretreated with KOH (1.4 M) to a pH of 10 and saturated with NaCl(s). The resulting MS data
are summarized in Table 3. These results demonstrate that derivatization with either ECF or
TCECF yields more qualifier ions as well as the molecular ions for the carbamate derivatives,
thus facilitating molecular discrimination. Furthermore, the addition of three chlorine atoms to
the TCECF-derivatized molecules allowed for unique isotopic peak patterns, providing each
molecule with a more easily identifiable fragmentation signature. Frison [28] previously reported
the MS advantages of TCECF derivatization on the mass spectral discrimination of mephedrone
from methanolic solutions of seized drugs containing mephedrone. At the time of this writing,
TCECF-derivatization has not been reported for the analysis of any other cathinone analogs, and
the derivatization of cathinone analogs with ECF has never before been reported. Additionally,
to our knowledge this work represents the first demonstration of in-matrix alkylchloroformate
derivatization of cathinone analogs in oral fluid for subsequent SPME/GC-MS analysis
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.
Figure 12: EI mass spectrometric fragmentation (70 eV) of 2o cathinones derivatized with ECF.
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Figure 13: EI mass spectrometric fragmentation (70 eV) of 2o cathinones derivatized with
TCECF.
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Table 3: Summary of the Mass Spectrometric Fragmentation of Underivatized, ECF Derivatized
and TCECF Derivatized Cathinones.*

*Qualifier ions that are present in the derivatives but not in the underivatized mass spectra shown
in bold

3.5: Proposed Fragmentation of Alkyl Chloroformate-Derivatized Cathinones
Figures 14a and 14b illustrate the proposed EI fragmentation pathways of TCECF- and
ECF-derivatized cathinones, respectively. An in-depth analysis of the fragmentation of these
derivatives is given below.
Cleavage a for both ECF and TCECF produces a substituted benzyl ion at m/z 91
(mephedrone), m/z 95 (flephedrone) m/z 107 (methedrone), and m/z 121 (methylone, butylone).
The loss of CO and acetylene from the tropylium ion (m/z 91) observed in the mephedrone mass
spectrum results in a ion at m/z 65 as well [28]. These fragments are useful for the differentiation
of R1 and R2 groups.
Cleavage b for both ECF and TCECF results in the formation of the 4-methylbenzoyl

cation at m/z 119 (mephedrone), the 4-fluorobenzoyl cation at m/z 123 (flephedrone), the
4-methoxybenzoyl cation at m/z 135 (methedrone) and the 3,4-methylenedioxybenzoyl

cation at m/z 149 (methylone, butylone). These fragments are also useful for
differentiating R1 and R2 groups.

Cleavage c for both ECF and TCECF derivatives results in the well-documented

iminium ion, which is observed in straight chain cathinones and phenethylamines [31]. The

iminium ion is formed by an α-cleavage process and is highly favorable due to the location
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of the C=O bond [31]. The fragments are observed at m/z 58 (mephedrone, methylone,
methedrone, flephedrone) and m/z 72 (butylone). The formation of the iminium ion
facilitates the production of cleavage a [31].

Cleavage d after TCECF derivatization results in the formation of isotopic clusters of

the [CHR3-NMe-COO-CH2-CCl3]+ cation at m/z 232/4/6 (mephedrone, methylone,

methedrone, flephedrone, MDMA) and m/z 246/8/52 (butylone) due to the ethyl R3 group.
These clusters represent the base peak in all of the recorded mass spectra. This cleavage is
useful in differentiating R3 and R4 groups, but by itself is not very diagnostically useful.

Cleavage d after ECF derivatization results in the formation of [CHR3-N(Me)COO-

CH2-CH3]+ cation at m/z 130 (mephedrone, methylone, methedrone, flephedrone) and m/z
144 (butylone) and provides diagnostic information on the composition of the R3 and R4

groups.

Cleavage e after TCECF results in the formation of the [R1,2-Ph-CO-CHR3-

N(Me)(CO)]+ cation at m/z 204 (mephedrone), m/z 208 (flephedrone), m/z 220

(methedrone), m/z 234 (methylone) and m/z 248 (butylone). These fragment ions in

methylone and butylone add to the relative abundance of the already present m/z 234 and
248 ions, respectively, which result from cleavage d. When used in conjunction with
cleavages a and c, differentiation between R1, R2, R3/4 groups is possible.

Cleavage e after ECF derivatization results in the formation of the [N(Me)COO-CH2-

CH3]+ cation at m/z 102, and provides information about the composition of the R4 groups.

The m/z 102 fragment was present in all of the 2o cathinone derivatives investigated in this
study, since they all have the same R4 group. However, this fragment would be extremely

34

useful for cathinone compounds that contain unique R4 groups since it would allow
differentiation between R3 and R4 by comparing it to cleavage c.

Cleavage f after TCECF derivatization results in the formation of isotopic clusters of

the [CH2-CCl3]+ ion at 131/3/5 for all derivatives investigated. Since these fragments are
present in all derivatives they hold little diagnostic value.

Cleavage g after TCECF derivatization results in a low abundance [M – Cl]+ at m/z

316/8 (mephedrone), m/z 320/2 (flephedrone), m/z 332/4 (methedrone), m/z 346/8

(methylone) and m/z 360/2 (butylone). These fragments have similar discriminating value
to the fragments from cleavage e because they allow for the differentiating of R1, R2, R3 and

R4 groups and exhibit isotopic clustering; however, their low abundance makes these
fragments less advantageous.

While TCECF derivatization of 2o cathinones provides slightly more diagnostic ions

for MS discrimination, it was discovered that TCECF has limited solubility in aqueous

samples, making it an unsuitable reagent for oral fluid applications. ECF, on the other hand,
was deemed suitable for derivatization of cathinones in oral fluid due to its aqueous

solubility and the increase in the number of diagnostic ions for derivatives (compared to

underivatized analytes), which allows for improved mass spectrometric differentiation.
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Figure 14: Proposed fragmentation of 2o cathinones after TCECF (a) and ECF (b) derivatization

3.6: Investigation of DI-SPME on Recovery of Underivatized Cathinones
As with HS-SPME experiments, initial DI-SPME experiments demonstrated that while
DI-SPME was a suitable method for the isolation of 3o cathinones from aqueous solution,
underivatized 2o cathinones were not efficiently recovered (Figure 15). Since analyte volatility is
not a consideration for DI-SPME, these results suggest that the 2o amines do not partition well
into the PDMS fiber film, which caused their lack of extractability. 3o amines and MDMA were
able to adequately partition into the PDMS fiber film and were efficiently extracted using DISPME.
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Figure 15: Resulting chromatogram following DI-SPME of an underivatized aqueous mixed
cathinone standard (320 ng/mL), demonstrating the recovery of 3o cathinones and MDMA, while
2o cathinones are extracted inefficiently. SPME conditions as in Figure 6

3.7: Effect of ECF and TCECF Derivatization on Cathinone Recovery Using DI-SPME
Derivatization with ECF (Figure 16) and TCECF (Figure 17) drastically improved the
DI-SPME recovery of 2o cathinones from aqueous and oral fluid samples. The improvement in
recovery of the 2o cathinones following derivatization with ECF and TCECF indicates that the
alkylchloroformate derivatives are able to partition more efficiently into the PDMS fiber film.
Similar to what was observed in the HS-SPME experiments, however, 3o cathinones were not
recovered in the presence of ECF. This unexpected result was hypothesized to occur because of
an unanticipated derivatization reaction occurring with the 3o cathinones. It is postulated that this
unexpected derivatization reaction may occur either at the tertiary amine, forming a quaternary
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amine salt, or at the carbonyl oxygen. Further theoretical and practical research into this
hypothesis is required to adequately determine what is occurring to 3o cathinones in the presence
of ECF. All analytes were extracted in the presence of TCECF. While the peaks for MDMATCECF and naphyrone co-elute, they can easily be distinguished by searching m/z 232 and 126,
the base peaks of MDMA-TCECF and naphyrone, respectively (Figure 17).

Figure 16: Resulting chromatogram following DI-SPME of an ECF-derivatized mixed aqueous
cathinone standard (320 ng/mL), demonstrating the recovery of 2o ECF-derivatized cathinones
while showing that 3o cathinones were unable to be extracted. SPME conditions as in Figure 6.
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Figure 17: Resulting chromatogram following DI-SPME of a TCECF-derivatized mixed
aqueous cathinone standard (320 ng/mL), demonstrating the recovery of all 2o TCECFderivatized cathinones and 3o cathinones. SPME conditions as in Figure 6.

3.8: Comparison of HS and DI-SPME for the Efficient Recovery of Alkylchloroformate
Derivatized Cathinones from Aqueous Solutions
Sampling the headspace offers significant advantages over direct immersion sampling. In
terms of “cleanliness” of the extract, the headspace contains only volatile and semi-volatile
organic compounds, while the oral fluid matrix contains a variety of additional non-volatile
endogenous compounds which can potentially interfere with chromatographic analysis or
contribute to fiber fouling. The life expectancy of the fiber is enhanced when sampling the
headspace because background adsorption and matrix effects are reduced [62]. In this study the
life expectancy of the fiber was also prolonged when sampling the headspace rather than the oral
fluid matrix itself, since the sample pH was adjusted to a pH of 10 and direct exposure to such a
harsh alkaline environment severely reduced fiber lifetime.
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The TriPlus autosampler employed in this study was not compatible with automated DI
sampling of low sample volumes due to sampling depth limitations. Samples were consequently
diluted with 8 mL of deionized H2O to bring the total volume up to an adequate level for the
automated direct immersion of SPME fiber. Ideally, a small-volume insert could be used in the
SPME vial to bring the original sample volume up to an adequate sampling height without the
need for sample dilution.
The constraints of the autosampler for DI-SPME, combined with the decrease in fiber life
experienced with this sampling mode, resulted in HS-SPME being chosen as the optimal SPME
sampling mode.
3.9: Optimization of HS-SPME Parameters
The pretreatment of aqueous and oral fluid samples fortified with 2o cathinones and
derivatized with ECF was optimized to maximize recovery of derivatized cathinones from
samples using HS-SPME. It was determined that pH adjustment to a pH of 10 using 1.4 M KOH
and saturation with NaCl(s) allowed for the maximum recovery of ECF-derivatized 2o cathinones
(Figure 18). The alkaline pH adjustment causes the cathinones to exist in solution in the free
base rather than protonated forms, which eliminates ionic interactions that reduce analyte
partitioning into the headspace. The addition of salt disrupts the interactions between the analytes
and the water molecules in solution, allowing them to more easily partition into the headspace. In
the absence of pretreatment, mephedrone and butylone were inefficiently recovered, while
flephedrone, methedrone and methylone were not recovered at all. Optimal recoveries for all
analytes occurred in the presence of both NaCl and KOH.
To further maximize recoveries of ECF-derivatized cathinones, the extraction/incubation
temperature was optimized. The results of temperature optimization experiments are shown in
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Figure 19. The extraction/incubation temperature for flephedrone-ECF and mephedrone-ECF
was optimized at 90oC, while methedrone-ECF, methylone-ECF and butylone-ECF were most
efficiently extracted at 110oC. Consequently, the individual analyte optimum temperatures were
averaged and the final optimized temperature was determined to be 102oC.
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Figure 18: Effect of sample pretreatment on the recoveries of ECF-derivatized 2o cathinones.
Samples containing 100 μL of a 320 ng/mL aqueous mixed cathinone standard, 50 μL of ECF
and variable sample pretreatment were run in triplicate and the absolute abundances of the base
peak for each derivatized analyte were averaged. All ECF-derivatives exhibited maximum
recovery in the presence of KOH and NaCl. Error bars represent the standard deviation for three
trials.
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Figure 19: Extraction/incubation temperature optimization for recoveries of ECF-derivatized 2o
cathinones. Samples containing 100 μL of a 320 ng/mL aqueous mixed cathinone standard, 50
μL of ECF, 400 μL of 1.4 M KOH and saturated with NaCl(s) were prepared. The optimal
temperature was determined to be 102oC, which was the average of the optimum
extraction/incubation temperature for each individual analyte. Data represents the average of
three extraction trials with error bars representing one standard deviation.
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3.10: HS-SPME Calibration of ECF-Derivatized 2o Cathinones in Oral Fluid
Linear calibration curves for ECF-derivatized cathinones ranging in concentration from
1-320 ng/mL were produced using HS-SPME (Figure 20). Because the calibration data in Figure
20 was obtained before extraction/incubation temperature optimization experiments were
conducted, the extraction/incubation was set at 80oC for these experiments.
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Figure 20: Calibration solutions in simulated oral fluid spanning an MDMA concentration range
of 1–320 ng/mL were prepared as described in the Experimental Methods section and subjected
to HS-SPME/GC-MS to generate the calibration plot depicted above. All calibration solutions
were spiked with mephedrone-d3 and butylone-d3 (96 ng/mL) as internal standards. Mephedroned3 was used as an internal standard for flephedrone, mephedrone, methedrone and methylone.
Butylone-d3 was used as an internal standard for butylone. All other SPME and GC-MS
parameters as described in Experimental Methods section.
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3.11: DI-SPME Calibration of ECF-Derivatized 2o Cathinones in Oral Fluid
Linear calibration curves for ECF-derivatized cathinones were produced using DI-SPME
from 20-320 ng/mL (Figure 21). While HS-SPME was concluded to be a more suitable
sampling mode for the reasons described above, the DI calibration data is included here for the
sake of completeness.
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Figure 21: Calibration solutions in simulated oral fluid spanning an analyte concentration range
of 20–320 ng/mL were prepared as described in the Experimental Methods section and subjected
to DI-SPME/GC-MS to generate the calibration plot depicted above. All calibration solutions
were spiked with MDMAd-5 as internal standard at 30 ng/mL. All other SPME and GC-MS
parameters as described in Experimental Methods section.
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3.12: Accuracy of DI-SPME Method
The accuracy of the DI-SPME method was determined by analysis of high (240 ng/mL)
and low (60 ng/mL) level spiked blind oral fluid samples and calculating target analyte
concentrations off of the appropriate calibration curves generated on the same day as the blind
sample analysis. The calculated analyte concentrations were compared to the true concentrations
to determine the % error of the quantification. Accuracy data is presented in Table 4.
Accuracies ranged between 1-10% with an average error of 5 %.

Table 4: Accuracy Data for Oral Fluid Samples Analyzed by DI-SPME/GC-MS*
Accuracy (% Error)
High
Low
(240 ng/mL) (60 ng/mL) Average**
Flephedrone-ECF
-7.75
10.53
9.14
Mephedrone-ECF
2.68
-1.14
1.91
MDMA-ECF
-8.84
-1.53
5.185
Methedrone-ECF
4.59
2.84
3.715
Methylone-ECF
2.68
-8.19
5.435
Butylone-ECF
6.61
5.66
6.135
Mean Accuracy (all analytes)
5.232
*Results calculated using calibration curve equations from Figure 21. MDMAd-5 (30 ng/mL)
was used as an internal standard.
**Average of absolute values of errors
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3.13: Limit of Detection and Limit of Quantitation of DI and HS-SPME Methods
The limit of detection (LOD) is the lowest concentration of an analyte that can be reliably
distinguished from a blank. The limit of quantification (LOQ) is the concentration of an analyte
at which a positive result can be reported with a high degree of certainty. The LOD (Equation 2)
and LOQ (Equation 3) can be determined from regression statistics using the following
equations [63]:
Equation 2:

LOD =

3.3 𝑠𝑦

Equation 3:

LOQ =

10 𝑠𝑦

𝑚

𝑚

where sy is the standard deviation associated with y and m is the slope of the regression
line. The LOD and LOQ data determined for the HS and DI-SPME methods are shown in Table
5. LOD values for ECF-derivatives ranged from 12 to 33 ng/mL for HS-SPME and 6 to 49
ng/mL for DI-SPME. LOQ values ranged from 37 to 99 ng/mL for HS-SPME and 19 to 148
ng/mL for DI-SPME. In general, compared with DI-SPME, HS-SPME produced a lower LOD
and LOQ for ECF-derivatives of flephedrone, mephedrone and methedrone while DI-SPME
resulted in a lower LOD and LOQ for methylone and butylone.

Table 5: LOD and LOQ Values for HS- and DI-SPME Methods Determined from Linear
Regression Statistics
HS-SPME
DI-SPME
LOD
LOQ
LOD
LOQ
Analyte
(ng/mL) (ng/mL)
(ng/mL)
(ng/mL)
Flephedrone-ECF
20.45
61.99
48.72
147.63
Mephedrone-ECF
14.46
43.85
15.5
46.97
Methedrone-ECF
16.44
49.82
19.96
60.48
Methylone-ECF
32.77
99.39
15.45
46.83
Butylone-ECF
12.11
36.7
6.13
18.57
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3.14: Application of Optimized Method to the Qualitative Analysis of 13 Amphetamines and
Cathinones in Oral Fluid
To illustrate the wide applicability of the HS-SPME/GC-MS method developed in this
work to the extraction, separation and identification of a wide variety of abused drugs, a mixed
oral fluid sample fortified with eight commonly abused amphetamines (amphetamine,
methamphetamine, PMA, PMMA, MDA, MDEA, MBDB, MDMA) and five 2° cathinones was
analyzed. In-matrix ECF derivatization was employed after pretreatment with KOH (1.4 M,
pH=10) and NaCl(s). The method was able to successfully extract, separate and detect all 13
drugs (Figure 22). While MDEA-ECF and methedrone-ECF were observed to co-elute with the
GC temperature program employed, their base peaks and qualifier ions are unique to each
molecule, thus allowing their mass spectral resolution.

Figure 22: GC after HS-SPME of a mixed cathinone and amphetamine standard solution (320
ng/mL) in oral fluid derivatized with ECF (50 μL) after pretreatment with KOH (1.4 M) to a pH
of 10 and saturated with NaCl(s), demonstrating the applicability of the method to a large variety
of abused stimulant drugs of abuse. 100 μm PDMS fiber, 102oC extraction/incubation
temperature, 10 min extraction time, 10 min incubation time, 6 min desorption time, 250oC
desorption temperature.
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3.15: Application of DI and HS-SPME Methods to Commercial Saliva Collection Kit
The optimized DI-SPME method was applied to a mock OF sample collected using the
Intercept oral fluid collection device as described in Section 2.11. The resulting GC is shown in
Figure 23. Although TCECF was sparingly soluble in water, the resulting TCECF-derivatized 2o
cathinones could be recovered using DI-SPME. The 3o cathinones were not recovered during this
experiment.

Figure 23: GC after DI-SPME from commercial saliva swab exposed to a 16 ng/mL mixed
cathinone solution as described in Section 2.11. SPME conditions as in Figure 6.
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3.16: Further HS-SPME Parameter Optimizations To Consider
The HS-SPME method reported here would benefit from further parameter optimization,
including incubation, extraction and desorption times; SPME fiber film thickness; and choice of
fiber phase. Optimization of incubation and desorption time could further reduce total sampling
time. Optimization of extraction time could further optimize analyte recoveries. Optimization of
SPME fiber film thickness and phase might offer improved analyte recoveries, since the analytes
or their alkylchloroformate dervatives might more readily partition into a different fiber phase or
film thickness.
3.17: Future Work
Future work on this project should include additional HS-SPME parameter optimization
(outlined in section 3.14) and further calibration studies to determine intra/interday
reproducibility. Additional accuracy and precision studies should take place concurrently. The
stability of the cathinone drugs and their alkylchloroformate derivatives in oral fluid should also
be studied by re-analyzing prepared samples after allowing them to sit in the autosampler tray for
24 - 48 hours (or other designated time periods), and comparing the quantified results to those
obtained when the samples were initially run. Derivatization with other alkylchloroformate
reagents should be explored to determine which reagent is most optimal for the recovery of
cathinones in oral fluid as well as determining which provides the best MS selectivity. The
failure to detect the tertiary amines in the presence of alkylchloroformate derivatizing reagents
must be investigated to determine whether these compounds are in fact reacting to form
unanticipated products. Finally, a more rigorous evaluation of method applicability to various
commercially available oral fluid drug-testing platforms must be undertaken.
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Chapter 4: Conclusions
HS-SPME was determined to be a suitable extraction method for the isolation of 2o
cathinones derivatized with ECF in oral fluid. ECF derivatives were optimally extracted using a
100 μm PDMS fiber at 102o C after being pretreated with base and salt. Linear calibration curves
were produced using both HS and DI-SPME at ranges of 1-320 and 20-320 ng/mL, respectively.
Blind sample studies analyzed using DI-SPME/GC-MS demonstrated accuracies of 1-10%. The
HS-SPME method produced LODs between 12-33 ng/mL and LOQs between 37-99 ng/mL for
the five target 2o cathinones. The DI-SPME method produced LODs between 6-49 ng/mL and
LOQs between 19-148 ng/mL for the target analytes. HS-SPME was determined to be a more
suitable extraction mode due to increased fiber lifetime, compatibility with the instrument
autosampler, and the elimination of background adsorption and matrix effects. Further HSSPME parameter optimization is required before the method can be considered completely
optimized. In particular, further experiments are necessary to understand the derivatization and
extraction behavior of the tertiary cathinones, and the method must be improved to isolate these
compounds. Additionally, in order to fully validate the method, its application to oral fluid
samples collected by various commercially available collection kits will need to be explored in
more depth, and, finally, the method must be evaluated and validated on oral fluid samples
collected from actual users.
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